Medicinal cannabis delivery systems: A perspective
In recent years, cannabis derivatives have been proposed for the treatment of various medical conditions, including pain, inflammation, epilepsy, sleep disorders, multiple sclerosis, anorexia, schizophrenia, neurodegenerative diseases, nausea, and cancer. While the benefits of cannabis derivatives, primarily cannabinoids, have been demonstrated and continue to be studied, their use presents various challenges associated with their low water solubility, rapid metabolism, erratic and poor bioavailability, and erratic pharmacokinetics, which directly affect their efficacy. In this context, a great deal of research is being carried out to overcome these drawbacks by designing delivery systems capable of improving solubility/bioavailability, potency, and efficacy, while addressing the purity and quality issues required by the pharmaceutical industry. This article aims to critically review the major trends and challenges in designing controlled-release cannabinoid delivery systems and their potential application in the pharmaceutical industry.
- Zuardi AW. History of cannabis as a medicine: A review. Braz J Psychiatry. 2006;28:153-157. doi: 10.1590/S1516-44462006000200015
- Missouri Botanical Garden. Cannabis sativa L. Missouri Botanical Garden; 2013. Available from: https://www. tropicos.org/name/21302042 [Last accessed on 2024 Jul 30].
- Flores-Sanchez IJ, Verpoorte R. Secondary metabolism in Cannabis. Phytochem Rev. 2008;7:615-639. doi: 10.1007/s11101-008-9094-4
- De Backer B, Debrus B, Lebrun P, et al. Innovative development and validation of an HPLC/DAD method for the qualitative and quantitative determination of major cannabinoids in cannabis plant material. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(32):4115-4124. doi: 10.1016/j.jchromb.2009.11.004
- McPartland JM, Russo EB. Cannabis and cannabis extracts: Greater than the sum of their parts? J. Cannabis Ther. 2001;1(3-4):103-132. doi: 10.1300/J175v01n03_08
- Atakan Z. Cannabis, a complex plant: Different compounds and different effects on individuals. Ther Adv Psychopharmacol. 2012;2(6):241-254. doi: 10.1177/204512531245758
- ElSohly MA, Slade D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci. 2005;78(5):539-548. doi: 10.1016/j.lfs.2005.09.011
- Grotenhermen F, Russo E, editors. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Binghamton, NY: Routledge; 2013.
- Wright S, Wilkhu J. U.S. Patent No. 11,426,362. Washington, DC: U.S. Patent and Trademark Office; 2022.
- Wilkhu J, Bender J. U.S. Patent Application No. 16/959,357. Washington, DC: U.S. Patent and Trademark Office; 2021.
- De Vries JA, Fernandez Cid MV, Heredia Lopez AM, Eiroa Martínez CM. U.S. Patent No. 10,245,237. Washington, DC: U.S. Patent and Trademark Office; 2019.
- Sengupta A, Roychoudhury SK. Triglyceride composition of Sesamum indicum seed oil. J Sci Food Agric. 1976;27(2):165-169. doi: 10.1002/jsfa.2740270214
- Lv P, Zhang D, Guo M, et al. Structural analysis and cytotoxicity of host-guest inclusion complexes of cannabidiol with three native cyclodextrins. J Drug Deliv Technol. 2019;51:337-344. doi: 10.1016/j.jddst.2019.03.015
- Palrasu M, Wright L, Patel M, et al. Perspectives on challenges in cannabis drug delivery systems: Where are we? Med Cannabis Cannabinoids. 2022;5(1):102-119. doi: 10.1159/000525629
- Bruni N, Della Pepa C, Oliaro-Bosso S, Pessione E, Gastaldi D, Dosio F. Cannabinoid delivery systems for pain and inflammation treatment. Molecules. 2018;23(10):2478. doi: 10.3390/molecules23102478
- Casiraghi A, Musazzi UM, Centin G, Franzè S, Minghetti P. Topical administration of cannabidiol: Influence of vehicle-related aspects on skin permeation process. Pharmaceuticals (Basel). 2020;13(11):337. doi: 10.3390/ph13110337
- Solowij N, Broyd SJ, van Hell HH, Hazekamp A. A protocol for the delivery of cannabidiol (CBD) and combined CBD and Δ9-tetrahydrocannabinol (THC) by vaporisation. BMC Pharmacol Toxicol. 2014;15:58. doi: 10.1186/2050-6511-15-58